Connor Clark & Lunn Investment Management Ltd. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 789.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,512 shares of the medical research company's stock after purchasing an additional 201,945 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.13% of IQVIA worth $44,708,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in IQV. Private Trust Co. NA boosted its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co boosted its position in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. grew its stake in IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares in the last quarter. Huntington National Bank increased its position in shares of IQVIA by 7.4% during the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company's stock worth $192,000 after purchasing an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after buying an additional 56 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Truist Financial restated a "buy" rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $249.05.
Check Out Our Latest Stock Analysis on IQVIA
IQVIA Price Performance
IQVIA stock traded up $3.97 during mid-day trading on Friday, reaching $185.40. 1,100,331 shares of the company were exchanged, compared to its average volume of 1,225,762. The company has a fifty day simple moving average of $196.63 and a 200-day simple moving average of $210.69. The firm has a market cap of $32.69 billion, a PE ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $256.34.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
